Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3506-3514

  Ide, Munenori ^a   Kato, Toshihide ^a   Ogata, Kyoichi ^a   Mochiki, Erito ^a   Kuwano, Hiroyuki ^a   Oyama, Tetsunari ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; KI 67 ANTIGEN; MUCIN 5AC; MUCIN 6; PROTEIN P53; STRATIFIN; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CELL CYCLE; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TUMOR GROWTH;

14-3-3 PROTEINS; ADENOCARCINOMA; AGED; DISEASE PROGRESSION; EXONUCLEASES; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-17; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUCIN 5AC; MUCIN-6; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEPRILYSIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868207596     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2437-9     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Surveillance, Epidemiology, and End Results. SEER stat fact sheets: Stomach.http://seer.cancer.gov/statfacts/html/stomach.html. Accessed 11 June 2012.
3. Moll R, Divo M, Langbein L. The human keratins: Biology and pathology. Histochem Cell Biol. 2008;129:705-33.
4. Karantza V. Keratins in health and cancer: More than mere epithelial cell markers. Oncogene. 2011;30:127-38.
5. Moll R, Franke WW, Volc-Platzer B, Krepler R. Different keratin polypeptides in epidermis and other epithelia of human skin: A specific cytokeratin of molecular weight 46,000 in epithelia of the pilosebaceous tract and basal cell epitheliomas. J Cell Biol. 1982;95:229-85.
6. Troyanovsky SM, Guelstein VI, Tchipysheva TA, Krutovskikh VA, Bannikov GA. Patterns of expression of keratin 17 in human epithelia: Dependency on cell position. J Cell Sci. 1989;93:419-26. (Pubitemid 19188086)
7. Troyanovsky SM, Leube RE, Franke WW. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur J Cell Biol. 1992;59:127-37.
8. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: Application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29:359-67. (Pubitemid 40321972)
9. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115:695-702. (Pubitemid 33051536)
10. Miettinen M, Nobel MP, Tuma BT, et al. Keratin 17: Immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Appl Immunohistochem. 1997;5:152-9.
11. Kim MA, Lee HS, Yang HK, Kim WH. Cytokeratin expression profile in gastric carcinomas. Hum Pathol. 2004;35:576-81. (Pubitemid 38656942)
12. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: Is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol. 2007;128:255-9. (Pubitemid 47262623)
13. Ide M, Nakajima T, Asao T, Kuwano H. Inactivation of 14-3-3 sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. Cancer Lett. 2004;207:241-9. (Pubitemid 38457046)
14. Barua RR, Uozaki H, Chong JM, et al. Phenotype analysis by MUC2, MUC5AC, MUC6, and CD10 expression in Epstein-Barr virus-associated gastric carcinoma. J Gastroenterol. 2006;41: 733-9. (Pubitemid 44446125)
15. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestinespecific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199:36-40. (Pubitemid 36054727)
16. Moll R, Moll I, Wiest W. Changes in the pattern of cytokeratin polypeptides in epidermis and hair follicles during skin development in human fetuses. Differentiation. 1982;23:170-8. (Pubitemid 13144648)
17. Jiang CK, Flanagan S, Ohtsuki M, Shuai K, Freedberg IM, Blumenberg M. Disease-activated transcription factor: Allergic reactions in human skin cause nuclear translocation of STAT-91 and induce synthesis of keratin K17. Mol Cell Biol. 1994;14: 4759-69. (Pubitemid 24196826)
18. Wei KJ, Zhang L, Yang X, et al. Expression of cytokeratin 17 protein in oral squamous cell carcinoma in vitro and in vivo. Oral Dis. 2009;15:111-7.
19. Takahashi H, Shikata N, Senzaki H, Shintaku M, Tsubura A. Immunohistochemical staining patterns of keratins in normal oesophageal epithelium and carcinoma of the oesophagus. Histopathology. 1995;26:45-50.
20. Wetzels RH, Schaafsma HE, Leigh IM, et al. Laminin and type VII collagen distribution in different types of human lung carcinoma: Correlation with expression of keratins 14, 16, 17 and 18. Histopathology. 1992;20:295-303.
21. Smedts F, Ramaekers F, Troyanovsky S, et al. Keratin expression in cervical cancer. Am J Pathol. 1992;141:497-511.
22. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74. (Pubitemid 32878711)
23. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433: 119-29. (Pubitemid 28401168)
24. Thike AA, Iqbal J, Cheok PY, et al. Triple negative breast cancer: Outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol. 2010;34:956-64.
25. Larsson K, Eriksson C, Schwenk JM, et al. Characterization of PrEST-based antibodies towards human cytokeratin-17. J Immunol Methods. 2009;342:20-32.
26. Economescu MC, Necula LG, Dragu D, et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010;57:1453-64.
27. Pacelli F, Papa V, Caprino P, Sgadari A, Bossola M, Doglietto GB. Proximal compared with distal gastric cancer: Multivariate analysis of prognostic factors. Am Surg. 2001;67:697-703. (Pubitemid 33739092)
28. Tajima Y, Yamazaki K, Makino R, et al. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer. 2007;96:631-8.
29. Simpson PT, Gale T, Reis-Filho JS, et al. Distribution and significance of 14-3-3 sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol. 2004;202:274-85. (Pubitemid 38325236)
30. O'Hare MJ, Ormerod MG, Monaghan P, Lane EB, Gusterson BA. Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation. 1991;46:209-21.
31. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: Recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-11. (Pubitemid 44624171)
32. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34. (Pubitemid 47219710)
33. Tanaka K, Hatada T, Kobayashi M, et al. The clinical implication of 14-3-3 sigma expression in primary gastrointestinal malignancy. Int J Oncol. 2004;25:1591-7.
34. Muhlmann G, Ofner D, Zitt M, et al. 14-3-3 sigma and p53 expression in gastric cancer and its clinical applications. Dis Markers. 2010;29:21-9.
35. Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature. 2006;441:362-5. (Pubitemid 44050202)
36. Ausch C, Buxhofer-Ausch V, Olszewski U, et al. Caspasecleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol. 2009;35:1164-8.
37. Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer. 2007;97:550-6. (Pubitemid 47258457)
38. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009;27:2177-84.
39. Knosel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I. Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol. 2006;28:167-75. (Pubitemid 44427400)
40. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006;12:4185-91.
41. Kim S, Coulombe PA. Intermediate filament scaffolds fulfill mechanical, organizational, and signaling functions in the cytoplasm. Genes Dev. 2007;21:1581-97. (Pubitemid 47026362)
42. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet. 2010;42:910-4.
43. Shi X, Jin L, Dang E, Chang T, Feng Z, Liu Y, Wang G. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Investig Dermatol. 2011;131:2401-8.
44. Bockelmann R, Horn T, Gollnick H, Bonnekoh B. Interferongamma- dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: Exploration of pharmaco- and gene-Therapeutic effects. Skin Pharmacol Physiol. 2005;18: 42-54. (Pubitemid 40082228)
45. Chang T, Sun L, Wang Y, et al. Inhibition of keratin 17 expression with antisense and RNAi strategies: Exploring novel therapy for psoriasis. Exp Dermatol. 2011;20:555-60.